Search Results 721-730 of 18312 for alopecia

1. A Study to Evaluate Safety of Enapotamab Vedotin in Patients with Solid Tumors - Mayo Clinic

   Toxic effects of prior anti-cancer therapy considered as chronic, such as chemotherapy-induced fatigue, alopecia, or anorexia of ≤ Grade 2, where no more ...

2. Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination with Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer - Mayo Clinic

   ... alopecia;; Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs. If clarification is ...

3. A Study to Evaluate AVB-S6-500 with Paclitaxel vs Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer - Mayo Clinic

   alopecia. Exclusion Criteria: - Tumors in the breast or bone - Untreated central nervous system (CNS) metastases. Subjects requiring corticosteroid therapy ...

4. A Study to Test Adding Pembrolizumab to Olaparib Alone as Therapy for Patients with Pancreatic Cancer That Has Spread with Inherited BRCA Mutations - Mayo Clinic

   ... alopecia. Zubrod performance status of 0-1. Patients must have a complete medical history and physical exam within 28 days prior to registration: Absolute ...

5. Meet The Faculty - Dermatopathology Fellowship (Minnesota) - Mayo Clinic College of Medicine & Science

   Her clinical and academic interests include autoimmune blistering disease, alopecia, and digital pathology. Outside of work, you might find her training for ...

6. Ascorbic Acid And Chemotherapy For The Treatment Of Relapsed Or Refractory Lymphoma, CCUS, And Chronic Myelomonocytic Leukemia - Mayo Clinic

   ... alopecia. ARM E REGISTRATION: Absolute neutrophil count (ANC) ≥ 500/mm^3 (obtained ≤ 7 days prior to registration). ARM E REGISTRATION: Platelet count ...

7. Study of bb21217 in Multiple Myeloma - Mayo Clinic

   Recovery to ≤ Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 2 neuropathy. Ability and ...

8. Oral lichen planus - Symptoms and causes - Mayo Clinic

   This ongoing inflammatory condition results in white, lacy patches or red, swollen tissues or open sores inside your mouth that may cause burning or pain.

9. A Study to Evaluate PDS0101 and Pembrolizumab Combination to Treat Subjects with HPV16 + Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma - Mayo Clinic

   Subjects with ≤Grade 2 neuropathy and ≤Grade 2 alopecia are an exception to this criterion and may qualify for therapy. Note: If participant received ...

10. TheraSphere With and Without Durvalumab and Tremelimumab for HCC - Mayo Clinic

    Patients with vitiligo or alopecia 2. Patients with hypothyroidism (e.g. following Hashimoto's syndrome) stable on hormone replacement therapy 3. Any ...